Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04371198 · ClinicalTrials.gov registry record · NA
Patient-Derived Organoids for Rectal Cancer
A NA study of Rectum Cancer, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04371198 is a NA study of Rectum Cancer that has completed, run by Duke University. The registered enrollment target is 20 participants, below the 197-participant average among 4 other Rectum Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04371198, a NA study of Rectum Cancer, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the feasibility of establishing patient-derived organoids from pre-treatment rectal adenocarcinoma biopsies.
Conditions Studied
Interventions
- OTHER Biopsy
Study Locations (1)
North Carolina
- Duke Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2022-08-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04371198
The ClinicalTrials.gov registry entry for NCT04371198 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 4 other Rectum Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectum Cancer appearing as the primary indexed condition, and to 1 intervention - of which Biopsy is the first listed.
NCT04371198 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04371198 about?
NCT04371198 is a clinical study titled "Patient-Derived Organoids for Rectal Cancer". The purpose of this study is to determine the feasibility of establishing patient-derived organoids from pre-treatment rectal adenocarcinoma biopsies.
What is the current status of trial NCT04371198?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2020-09-18. Estimated completion is 2022-08-17.
What conditions does trial NCT04371198 study?
This clinical trial studies the following conditions: Rectum Cancer.
What interventions are being tested in trial NCT04371198?
The interventions under investigation include: Biopsy (OTHER).
Who is sponsoring clinical trial NCT04371198?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04371198 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectum Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Adaptive Symptom Self-Management Immunotherapy Study
RECRUITING · NA
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.